RAPIVAB

LOE ApproachingSM

peramivir

NDAINTRAVENOUSSOLUTION
Approved
Dec 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
12

Mechanism of Action

Neuraminidase Inhibitors

Pharmacologic Class:

Neuraminidase Inhibitor

Clinical Trials (5)

NCT02635724Phase 3Completed

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

Started Dec 2015
74 enrolled
Influenza
NCT02369159Phase 3Completed

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Started Mar 2015
137 enrolled
Influenza
NCT02665351Phase 2/3Completed

Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections

Started Feb 2011
16 enrolled
Influenza
NCT01224795Phase 3Terminated

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Started Oct 2010
1 enrolled
Influenza
NCT01146353N/AWithdrawn

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

Started Feb 2010
0
InfluenzaRenal Failure

Loss of Exclusivity

LOE Date
May 7, 2027
14 months away
Patent Expiry
May 7, 2027

Patent Records (2)

Patent #ExpiryTypeUse Code
10391075
Feb 12, 2027
U-3069
8778997
May 7, 2027
U-3069